Coherus Oncology (CHRS) Goodwill & Intangibles (2014 - 2026)

Coherus Oncology has reported Goodwill & Intangibles for 13 years, with the latest figure at $45.6 million in Q1 2026.

• Quarterly Goodwill & Intangibles fell 13.9% year-over-year to $45.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.6 million (down 13.9% YoY) and the FY2025 annual result came in at $46.2 million, down 13.81% from the prior year.
• Goodwill & Intangibles retreated to $45.6 million in Q1 2026 per CHRS's latest filing, from $46.2 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $71.7 million in Q4 2023 and troughed at $3.6 million in Q1 2022.
• A 5-year average of $36.2 million and a median of $46.5 million in 2023 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles surged 1108.45% in 2023, then declined 25.15% in 2024.
• Over 5 years, Goodwill & Intangibles stood at $5.9 million in 2022, then soared by 1108.45% to $71.7 million in 2023, then slipped by 25.15% to $53.6 million in 2024, then dropped by 13.81% to $46.2 million in 2025, then slipped by 1.35% to $45.6 million in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $45.6 million, $46.2 million, and $49.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.